FAP and neoplasm: Anti-FAP-α CAR T cell treatment has shown compelling efficacy in multiple preclinical models of a variety of solid tumours [217,218,219], although work by Tran et al., 2013 showed limited anti-tumoural effects of anti-FAP-α CAR T cell and lethal ‘on target, off-tumour’ toxicity [220].